Contact Us
Drug Search Results
More Filters [+]

Rurioctocog alfa pegol

Alternative Names: rurioctocog alfa pegol, bax-855, bax 855, bax855, tak-660, tak 660, tak660, adynovate
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Takeda is developing rurioctocog alfa pegol (ADYNOVI/ADYNOVATE) as a treatment for hemophilia A. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04158934)

Mechanisms of Action: FVIII Mimetic

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Belgium | Brazil | Colombia | Croatia | Denmark | Germany | Hong Kong | Hungary | Ireland | Italy | Japan | Malaysia | Mexico | Netherlands | New Zealand | Norway | Portugal | Russia | Serbia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rurioctocog alfa pegol

Countries in Clinic: Austria, Belgium, Bulgaria, Canada, China, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Korea, Malaysia, Netherlands, Norway, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Hemophilia A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
FVIII < 1%

P3

Completed

Hemophilia A

2024-10-29

FVIII <1%

P3

Completed

Hemophilia A

2024-09-05

CTR20223385

P3

Recruiting

Hemophilia A

None

Recent News Events

Date

Type

Title

04/02/2024

PubMed

 Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

12/08/2023

PubMed

 Hemostatic potential of recombinant von Willebrand factor and standard or pegylated extended half-life recombinant factor VIII on thrombus formation under high shear flow.

12/05/2022

News Article

 Octapharma to present new clinical data and studies at ASH 2022 to demonstrate its continued mission to meet the challenges faced by people with bleeding disorders

12/13/2021

News Article

 Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021

07/20/2021

News Article

 Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders

06/18/2021

News Article

 $680 Million PEGylated Global Market to 2026 - by Type, Application, End-user Industry and Geography

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions